Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Clement Lo(Monash Health), Sophia Zoungas(University of Sydney), Alan Cass(University of Sydney), Vlado Perkovic(New South Wales Department of Health), Sunil V. Badve(UNSW Sydney), Yoichiro Hirakawa(University of Leicester), Min Jun(New South Wales Department of Health), Ying Wang(Shanghai University of Traditional Chinese Medicine), Jin Lin(Capital Medical University), Tadashi Toyama(UNSW Sydney), Carmel M. Hawley(The University of Queensland), Helen Pilmore
Cited by 101
Related Papers
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k